BR0212641A - Método para identificação de antìgeno, método para a produção de um composto, método para a inibição de proliferação de células, método para o tratamento de câncer, composição e seu uso - Google Patents
Método para identificação de antìgeno, método para a produção de um composto, método para a inibição de proliferação de células, método para o tratamento de câncer, composição e seu usoInfo
- Publication number
- BR0212641A BR0212641A BR0212641-9A BR0212641A BR0212641A BR 0212641 A BR0212641 A BR 0212641A BR 0212641 A BR0212641 A BR 0212641A BR 0212641 A BR0212641 A BR 0212641A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- composition
- cell proliferation
- cell
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title abstract 8
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 230000004663 cell proliferation Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 abstract 3
- 230000004540 complement-dependent cytotoxicity Effects 0.000 abstract 3
- 231100000433 cytotoxic Toxicity 0.000 abstract 2
- 230000001472 cytotoxic effect Effects 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- 230000002927 anti-mitotic effect Effects 0.000 abstract 1
- 239000003080 antimitotic agent Substances 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 230000030833 cell death Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000000394 mitotic effect Effects 0.000 abstract 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Public Health (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
"MéTODO PARA IDENTIFICAçãO DE ANTìGENO, MéTODO PARA A PRODUçãO DE UM COMPOSTO, MéTODO PARA A INIBIçãO DE PROLIFERAçãO DE CéLULAS, MéTODO PARA O TRATAMENTO DE CâNCER, COMPOSIçãO E SEU USO". São fornecidos métodos e composições para o desenvolvimento de terapias eficazes contra o câncer, utilizando inibidores mitóticos que apresentam toxicidade geral limitada a células e tecidos normais, não cancerígenos. os métodos e composições utilizam compostos citotóxicos que compreendem um (compostos de) agente de ligação celular (tal como anticorpos) conjugado a um agente antimitótico (tal como maytansinóides). a presente invenção fornece ainda anticorpos que são substancialmente incapazes de induzir citotoxicidade mediada por células dependentes de anticorpos (ADCC) e/ou citotoxicidade dependente do complemento (CDC), de forma a garantir que o efeito terapêutico seja mediado principalmente pelo componente antimitótico do composto citotóxico e não pela morte celular indireta através de ADCC e/ou CDC. os anticorpos de acordo com a presente invenção são adicionalmente capazes de diferenciar entre antígenos de polipeptídeos que apresentam expressão mais alta sobre células cancerígenas em proliferação em comparação com células não-cancerígenas em proliferação.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31750401P | 2001-09-05 | 2001-09-05 | |
| PCT/US2002/028176 WO2003020909A2 (en) | 2001-09-05 | 2002-09-04 | Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0212641A true BR0212641A (pt) | 2005-04-12 |
Family
ID=23233944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0212641-9A Pending BR0212641A (pt) | 2001-09-05 | 2002-09-04 | Método para identificação de antìgeno, método para a produção de um composto, método para a inibição de proliferação de células, método para o tratamento de câncer, composição e seu uso |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1432446B1 (pt) |
| JP (2) | JP5224632B2 (pt) |
| KR (3) | KR20040044850A (pt) |
| CN (2) | CN1578673A (pt) |
| AT (1) | ATE506965T1 (pt) |
| AU (1) | AU2002332838B2 (pt) |
| BR (1) | BR0212641A (pt) |
| CA (1) | CA2457541C (pt) |
| DE (1) | DE60239881D1 (pt) |
| DK (1) | DK1432446T3 (pt) |
| HU (1) | HUP0500617A3 (pt) |
| IL (2) | IL160659A0 (pt) |
| MX (1) | MXPA04002084A (pt) |
| NZ (1) | NZ531515A (pt) |
| PL (1) | PL374363A1 (pt) |
| WO (1) | WO2003020909A2 (pt) |
| ZA (1) | ZA200401751B (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8088387B2 (en) * | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| PT3524611T (pt) * | 2003-05-20 | 2021-04-01 | Immunogen Inc | Agentes citotóxicos melhorados compreendendo novos maitansinóides |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| NO347360B1 (no) * | 2003-10-10 | 2023-09-25 | Immunogen Inc | Cellebindingsmiddelmaytansinoid-konjugat med formel trastuzumab-SMCC-DM1 eller trastuzumab-SIABDM1, fremgangsmåte for fremstilling av disse og en in vitro fremgangsmåte for å styre maytansinoider til en valgt cellepopulasjon eller for å eliminere celler, samt anvendelse. |
| PL2247304T3 (pl) * | 2008-04-02 | 2017-01-31 | Macrogenics, Inc. | Przeciwciała specyficzne wobec HER2/neu oraz sposoby ich zastosowania |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2026147C (en) * | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| IL144559A0 (en) * | 1999-03-01 | 2002-05-23 | Genentech Inc | Antibodies for cancer therapy and diagnosis |
| DE60039448D1 (de) * | 1999-10-29 | 2008-08-21 | Genentech Inc | Gegen das prostata-stammzellantigen (psca) gerichtete antikörper und deren verwendung |
| MXPA02007317A (es) * | 2000-01-26 | 2004-07-30 | Ventana Med Syst Inc | Un sistema para desarrollar ensayos para medicina personalizada. |
-
2002
- 2002-09-04 KR KR10-2004-7003327A patent/KR20040044850A/ko not_active Application Discontinuation
- 2002-09-04 DK DK02797854.3T patent/DK1432446T3/da active
- 2002-09-04 CN CNA02821529XA patent/CN1578673A/zh active Pending
- 2002-09-04 KR KR1020107011044A patent/KR20100061863A/ko not_active Application Discontinuation
- 2002-09-04 NZ NZ531515A patent/NZ531515A/en not_active IP Right Cessation
- 2002-09-04 CA CA2457541A patent/CA2457541C/en not_active Expired - Fee Related
- 2002-09-04 WO PCT/US2002/028176 patent/WO2003020909A2/en active Application Filing
- 2002-09-04 MX MXPA04002084A patent/MXPA04002084A/es active IP Right Grant
- 2002-09-04 AU AU2002332838A patent/AU2002332838B2/en not_active Ceased
- 2002-09-04 DE DE60239881T patent/DE60239881D1/de not_active Expired - Lifetime
- 2002-09-04 IL IL16065902A patent/IL160659A0/xx unknown
- 2002-09-04 EP EP02797854A patent/EP1432446B1/en not_active Expired - Lifetime
- 2002-09-04 HU HU0500617A patent/HUP0500617A3/hu unknown
- 2002-09-04 KR KR1020097019746A patent/KR20090104925A/ko not_active Application Discontinuation
- 2002-09-04 PL PL02374363A patent/PL374363A1/xx not_active IP Right Cessation
- 2002-09-04 AT AT02797854T patent/ATE506965T1/de not_active IP Right Cessation
- 2002-09-04 CN CNA2008101656506A patent/CN101446590A/zh active Pending
- 2002-09-04 JP JP2003525613A patent/JP5224632B2/ja not_active Expired - Fee Related
- 2002-09-04 BR BR0212641-9A patent/BR0212641A/pt active Pending
-
2004
- 2004-03-01 IL IL160659A patent/IL160659A/en not_active IP Right Cessation
- 2004-03-03 ZA ZA2004/01751A patent/ZA200401751B/en unknown
-
2010
- 2010-08-04 JP JP2010175090A patent/JP2010280691A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP1432446B1 (en) | 2011-04-27 |
| ATE506965T1 (de) | 2011-05-15 |
| EP1432446A4 (en) | 2004-09-08 |
| WO2003020909A3 (en) | 2003-11-20 |
| CA2457541C (en) | 2013-01-08 |
| JP5224632B2 (ja) | 2013-07-03 |
| KR20040044850A (ko) | 2004-05-31 |
| EP1432446A2 (en) | 2004-06-30 |
| IL160659A (en) | 2011-07-31 |
| HUP0500617A2 (hu) | 2005-10-28 |
| CN1578673A (zh) | 2005-02-09 |
| CA2457541A1 (en) | 2003-03-13 |
| NZ531515A (en) | 2007-11-30 |
| PL374363A1 (en) | 2005-10-17 |
| AU2002332838B2 (en) | 2007-08-02 |
| MXPA04002084A (es) | 2004-06-07 |
| WO2003020909A2 (en) | 2003-03-13 |
| IL160659A0 (en) | 2004-08-31 |
| ZA200401751B (en) | 2005-07-27 |
| DE60239881D1 (de) | 2011-06-09 |
| JP2005517155A (ja) | 2005-06-09 |
| DK1432446T3 (da) | 2011-07-18 |
| HUP0500617A3 (en) | 2012-05-02 |
| KR20090104925A (ko) | 2009-10-06 |
| JP2010280691A (ja) | 2010-12-16 |
| KR20100061863A (ko) | 2010-06-09 |
| CN101446590A (zh) | 2009-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0214457A (pt) | métodos para o tratamento de cáncer | |
| RS20050522A (en) | Protein kinase inhibiting tricyclic compounds that increase the effects of anti-neoplastic agents and therapeutic radiation | |
| BRPI0207961A8 (pt) | Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos. | |
| BRPI0407375A (pt) | Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos | |
| PT910382E (pt) | Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumores | |
| BRPI0413580A (pt) | composto, composição farmacêutica, e, métodos para tratar ou prevenir cáncer em um mamìfero em necessidade de tal tratamento, para modular a formação do fuso mitótico e para inibir a cinesina mitótica ksp | |
| MY136604A (en) | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting celll proliferation | |
| DOP2022000232A (es) | Compuestos de 2,4-dioxopirimidina inhibidores de cd73 | |
| BRPI0409879A (pt) | composições e métodos para imunoterapia especìfica wt1 | |
| BRPI0509653A (pt) | inibidores cinesina mitótica | |
| AU2006273692A8 (en) | 1,4-Dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them | |
| BR9908125A (pt) | Composto, composto dimérico, composição farmacêutica, uso do composto, processo compreendendo inibir células de câncer, e, processo terapêutico | |
| BR0208353A (pt) | Compostos de diidropirimidina substituìdos com ciano e seu uso para tratar doenças | |
| BR0208405A (pt) | Compostos de diidropirimina substituìdos com ciano e seu uso para tratar doenças | |
| BR0212641A (pt) | Método para identificação de antìgeno, método para a produção de um composto, método para a inibição de proliferação de células, método para o tratamento de câncer, composição e seu uso | |
| BR0311491A (pt) | Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero | |
| BRPI0413384A (pt) | inibidores da proteìna farnesil transferase como agentes antitumores | |
| BRPI0414700A (pt) | 6-[(substituìdo)fenil]triazolopirimidinas como agentes anti-cáncer | |
| BR0015597A (pt) | Uso de anticorpos como vacinas | |
| BR9808249A (pt) | Composição farmacêutica, processos para tratar câncer em um mamìfero e para a manufatura de um medicamento para o tratamento de câncer em um mamìfero, e, uso de um composto | |
| BR0215689A (pt) | Composição farmacêutica compreendendo arsênico para o tratamento de malignidade | |
| BR0116123A (pt) | Carbazóis antitumorais | |
| BR9813756A (pt) | Derivados da acronicina, seu processo de preparo e as composições farmacêuticas que as contêm | |
| BR0211436A (pt) | Método e composição para tratamento de câncer | |
| BRPI0416316A (pt) | combinação de um inibidor da farnesil transferase com um agente anti-hormonal para o tratamento de cáncer de mama |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |